Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications (Q28069639)

C. T. M. M. de Kanter

2

1 reference

R. J. de Knegt

3

1 reference

M. van der Valk

4

1 reference

J. P. H. Drenth

5

1 reference

D. M. Burger

6

1 reference

language of work or name

1 reference

December 2016

1 reference

Clinical Pharmacokinetics

1 December 2016

11 references

23 March 2019

21 March 2019

22 June 2019

28 September 2019

18 November 2019

14 December 2019

1 July 2020

20 July 2020

27 October 2020

21 December 2020

25 October 2022

12 references

23 March 2019

21 March 2019

22 June 2019

28 September 2019

18 November 2019

14 December 2019

1 July 2020

20 July 2020

27 October 2020

21 December 2020

25 October 2022

55

1 reference

issue

12

1 reference

page(s)

1471-1494

1 reference

Creative Commons Attribution-NonCommercial

copyright license

11 references

23 March 2019

21 March 2019

22 June 2019

28 September 2019

18 November 2019

14 December 2019

1 July 2020

20 July 2020

27 October 2020

21 December 2020

25 October 2022

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Drug-drug interactions during antiviral therapy for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Why the Treatment of Mental Disorders Is an Important Component of HIV Prevention among People Who Inject Drugs

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

What do drug transporters really do?

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

The importance of drug-drug interactions in the DAA era.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5107187

Psychiatric disorders among veterans with hepatitis C infection

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Clinical impairment of benzodiazepines--relation between benzodiazepine concentrations and impairment in apprehended drivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0407-2

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27317413

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40262-016-0407-2

1 reference

Dimensions Publication ID

1044568136

0 references

1 reference

1 reference

PubMed publication ID

27317413

1 reference